Quote:

---

Copycat of Leronlimab or just ahead of LL?

https://news.abbvie.com/2024-02-28-AbbVie-and...0OSE%2D230

---

In some ways it's the anti-thesis of leronlimab. Their drug OSE-230 activates ChemR23 which triggers an upregulation of M2 macrophages (anti-inflammatory). On the flipside it would downregulate M1 macrophages (inflammatory). Some TAMS (tumor associated macrophages) are M2 types but quite a few are M1 macrophages and protect the tumor against being destroyed. Definitely a mixed bag on effect. I took a look at a pre-clinical study and it showed p = .01 for survival, statistically significant but not overwhelming.

https://www.frontiersin.org/journals/immunolo...96731/full

Leronlimab promotes M2 macrophage upregulation so tumor and virus fighting responses are maintained. But the little trick leronlimab has is that CCR5 ligands are not being used to promote other inflammatory chemokines and are not being used for transport of those macrophages, But the other CCR and CXCR receptors are taking up the slack to provide homeostasis rather than an overreaction.